van Laar RK - Search Results

1

A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.

van Laar RK, Lincoln MT, van Laar BJ. van Laar RK, et al. Melanoma Res. 2019 Feb;29(1):19-22. doi: 10.1097/CMR.0000000000000492. Melanoma Res. 2019. PMID: 30320629

2

BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.

D'Alfonso TM, van Laar RK, Vahdat LT, Hussain W, Flinchum R, Brown N, John LS, Shin SJ. D'Alfonso TM, et al. Among authors: van laar rk. Breast Cancer Res Treat. 2013 Jun;139(3):705-15. doi: 10.1007/s10549-013-2604-0. Epub 2013 Jun 18. Breast Cancer Res Treat. 2013. PMID: 23774991

3

Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer.

Van Laar RK. Van Laar RK. BMC Med Genomics. 2012 Jul 2;5:30. doi: 10.1186/1755-8794-5-30. BMC Med Genomics. 2012. PMID: 22748043 Free PMC article. Clinical Trial.

4

Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival.

Van Laar RK. Van Laar RK. J Mol Diagn. 2011 May;13(3):297-304. doi: 10.1016/j.jmoldx.2010.12.003. Epub 2011 Mar 31. J Mol Diagn. 2011. PMID: 21458382 Free PMC article.

5

An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer.

Van Laar RK. Van Laar RK. Br J Cancer. 2010 Dec 7;103(12):1852-7. doi: 10.1038/sj.bjc.6605970. Epub 2010 Nov 30. Br J Cancer. 2010. PMID: 21119668 Free PMC article.

6

Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.

van Laar RK, Ma XJ, de Jong D, Wehkamp D, Floore AN, Warmoes MO, Simon I, Wang W, Erlander M, van't Veer LJ, Glas AM. van Laar RK, et al. Int J Cancer. 2009 Sep 15;125(6):1390-7. doi: 10.1002/ijc.24504. Int J Cancer. 2009. PMID: 19536816

7

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D. Horlings HM, et al. Among authors: van laar rk. J Clin Oncol. 2008 Sep 20;26(27):4435-41. doi: 10.1200/JCO.2007.14.6969. J Clin Oncol. 2008. PMID: 18802156

8

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM. Kok M, et al. Among authors: van laar rk. Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4. Breast Cancer Res Treat. 2009. PMID: 18311582

9

Location of, immunogenicity of and relationships between neutralization epitopes on the attachment protein (G) of Hendra virus.

White JR, Boyd V, Crameri GS, Duch CJ, van Laar RK, Wang LF, Eaton BT. White JR, et al. Among authors: van laar rk. J Gen Virol. 2005 Oct;86(Pt 10):2839-2848. doi: 10.1099/vir.0.81218-0. J Gen Virol. 2005. PMID: 16186240

10

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.

Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ. Tothill RW, et al. Among authors: van laar rk. Cancer Res. 2005 May 15;65(10):4031-40. doi: 10.1158/0008-5472.CAN-04-3617. Cancer Res. 2005. PMID: 15899792

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters